Colonic Expression and Synthesis of Interleukin 13 and Interleukin 15 in Inflammatory Bowel Disease
Overview
Biology
Authors
Affiliations
Unlabelled: A dysregulated local immune reaction with unbalanced cytokine expression seems essential in inflammatory bowel disease (IBD), i.e. ulcerative colitis (UC) and Crohn's disease (CD). Since the roles of interleukin (IL-)13 and IL-15 remain unclear, this study aimed at studying intestinal expression of IL-13 and IL-15 in IBD.
Methods: In colonic biopsies from 24 UC, 18 CD, and 12 controls IL-13 and IL-15 were measured using ELISA, and their gene expressions were assessed by RT-PCR. Leukocytes were visualised histochemically.
Results: Concentrations of IL-13 were decreased in UC (median 56 pg/mg tissue; interquartile range 30-99 pg/mg) compared to CD (82 pg/mg tissue; 41-122;P=0.004) and controls (83 pg/mg tissue; 18-134;P>0.05), and lower in active UC (53 pg/mg tissue; 33-96) than in inactive UC (80 pg/mg tissue; 65-99;P=0.02). IL-15 concentrations were higher in CD patients (34 pg/mg tissue; 24-53) as compared to controls (20 pg/mg tissue; 15-21;P=0.001) whilst being 22 pg/mg tissue (15-32) in UC. IL-13 mRNA and IL-15 mRNA were detected in 20% and 15%, respectively. Infiltration of leukocytes correlated inversely with IL-13 levels (P=0.02).
Conclusion: Active UC is associated with decreased colonic IL-13 suggesting that IL-13 levels are diminished as a part of UC exacerbations, or that exacerbations follow active downregulation of IL-13.
Immune response modulation in inflammatory bowel diseases by infection.
Feilstrecker Balani G, Dos Santos Cortez M, Picasky da Silveira Freitas J, de Melo F, Zarpelon-Schutz A, Teixeira K World J Gastroenterol. 2023; 29(30):4604-4615.
PMID: 37662864 PMC: 10472898. DOI: 10.3748/wjg.v29.i30.4604.
Sensitization of colonic nociceptors by IL-13 is dependent on JAK and p38 MAPK activity.
Barker K, Higham J, Pattison L, Chessell I, Welsh F, Smith E Am J Physiol Gastrointest Liver Physiol. 2023; 324(4):G250-G261.
PMID: 36749569 PMC: 10010921. DOI: 10.1152/ajpgi.00280.2022.
Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis.
Kinoshita N, Kakimoto K, Shimizu H, Nishida K, Numa K, Kawasaki Y J Clin Med. 2022; 11(17).
PMID: 36078882 PMC: 9456517. DOI: 10.3390/jcm11174952.
Targeting Certain Interleukins as Novel Treatment Options for Liver Fibrosis.
An S, Petrescu A, DeMorrow S Front Pharmacol. 2021; 12:645703.
PMID: 33841164 PMC: 8024568. DOI: 10.3389/fphar.2021.645703.
Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAE.
Laurent C, Deblois G, Clenet M, Moratalla A, Farzam-Kia N, Girard M Neurol Neuroimmunol Neuroinflamm. 2020; 8(1).
PMID: 33323466 PMC: 7745728. DOI: 10.1212/NXI.0000000000000931.